The researchers suggest certain refinements to the 2022 European LeukemiaNet classification model for patients aged 60 years or older receiving lower intensity treatment (LIT), including the adoption ...
– 26% (20/77) CR+CRh rate and 48% (37/77) ORR in efficacy-evaluable pivotal R/R mNPM1 AML population – – Robust responses observed across subgroups, regardless of co-mutations, number of prior lines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results